ECSP045278A - OXO-AZABYCLIC COMPOUNDS - Google Patents

OXO-AZABYCLIC COMPOUNDS

Info

Publication number
ECSP045278A
ECSP045278A EC2004005278A ECSP045278A ECSP045278A EC SP045278 A ECSP045278 A EC SP045278A EC 2004005278 A EC2004005278 A EC 2004005278A EC SP045278 A ECSP045278 A EC SP045278A EC SP045278 A ECSP045278 A EC SP045278A
Authority
EC
Ecuador
Prior art keywords
group
inclusive
integer
alkyl
formula
Prior art date
Application number
EC2004005278A
Other languages
Spanish (es)
Inventor
Bernard Gaudilliere
Henry Jacobelli
Catherine R Kostlan
Jack Li
Wen-Song Yue
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ECSP045278A publication Critical patent/ECSP045278A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto seleccionado de aquellos de la fórmula (I): en donde:X1, X2 y X3 representan N o -CR3 en donde R3 es lo descrito en la memoria descriptiva,· G1 representa un grupo seleccionado de aquellos de las fórmulas (i/a) e (i/b): en donde R4, R5, y R6 son lo definido anteriormente, · G2 representa un grupo seleccionado de enlace triple de carbono-carbono, -CH=C=CH-, C=O, C=S, S(O)n1 en donde n1 representa un número entero de 0 a 2 inclusive, y un grupo de la fórmula (i/c): en donde Y1 representa O, S, -NH o -N alquilo e Y2 representa O, S, -NH o -N alquilo,· n es un número entero de 0 a 6 inclusive, y m es un número entero de 0 a 7 inclusive,· Z1 representa -CR9R10, en donde R9 y R10 son lo definido en la memoria descriptiva,· A representa un sistema de anillo,· R1 representa un grupo seleccionado de H, alquilo, alquenilo, alquinilo, optativamente sustituido y el grupo de la fórmula (i/d): en donde p, Z2, B, q y G2 son lo definido en la memoria descriptivay optativamente, sus isómeros ópticos, N-óxidos y sales de ellos con el ácido o base farmacéuticamente aceptable, y productos medicinales que contienen los mismos son útiles como inhibidores específicos de la metaloproteasa de la matriz de tipo 13.A compound selected from those of the formula (I): where: X1, X2 and X3 represent N or -CR3 where R3 is as described in the specification, · G1 represents a group selected from those of the formulas (i / a) e (i / b): where R4, R5, and R6 are as defined above, · G2 represents a selected group of carbon-carbon triple bond, -CH = C = CH-, C = O, C = S, S (O) n1 where n1 represents an integer from 0 to 2 inclusive, and a group of the formula (i / c): where Y1 represents O, S, -NH or -N alkyl and Y2 represents O , S, -NH or -N alkyl, · n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive, · Z1 represents -CR9R10, where R9 and R10 are defined in memory descriptive, · A represents a ring system, · R1 represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of the formula (i / d): wherein p, Z2, B, q and G2 are what is defined in the specification and optional e, its optical isomers, N-oxides and salts thereof with the pharmaceutically acceptable acid or base, and medicinal products containing them are useful as specific inhibitors of type 13 matrix metalloprotease.

EC2004005278A 2002-03-08 2004-09-03 OXO-AZABYCLIC COMPOUNDS ECSP045278A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/003240 WO2003076416A1 (en) 2002-03-08 2002-03-08 Oxo azabicyclic compounds

Publications (1)

Publication Number Publication Date
ECSP045278A true ECSP045278A (en) 2004-10-26

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005278A ECSP045278A (en) 2002-03-08 2004-09-03 OXO-AZABYCLIC COMPOUNDS

Country Status (25)

Country Link
EP (1) EP1492775A2 (en)
JP (1) JP2005526070A (en)
KR (1) KR20040095270A (en)
CN (1) CN1738806A (en)
AP (1) AP2004003125A0 (en)
AR (1) AR039562A1 (en)
AU (2) AU2002249275A1 (en)
BR (1) BR0308280A (en)
CA (1) CA2478706A1 (en)
CO (1) CO5601020A2 (en)
EA (1) EA200401053A1 (en)
EC (1) ECSP045278A (en)
IL (1) IL163818A0 (en)
IS (1) IS7414A (en)
MA (1) MA27183A1 (en)
MX (1) MXPA04008681A (en)
NO (1) NO20044041L (en)
OA (1) OA12782A (en)
PA (1) PA8568501A1 (en)
PE (1) PE20031018A1 (en)
PL (1) PL372622A1 (en)
SV (1) SV2003001495A (en)
TN (1) TNSN04169A1 (en)
UY (1) UY27700A1 (en)
WO (2) WO2003076416A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (en) 2001-02-14 2002-09-30 Warner Lambert Co TRIAZOLO COMPOUNDS AS MMP INHIBITORS
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
EP1537098A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company LLC Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014866A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
BR0313384A (en) 2002-08-13 2005-07-12 Warner Lambert Co Chromone derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003250471A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
PA8578101A1 (en) 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
DE10360835A1 (en) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
AU2005238386A1 (en) * 2004-04-30 2005-11-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an MMP-13 inhibitor
CA2568756A1 (en) * 2004-06-15 2005-12-29 Astrazeneca Ab Substituted quinazolones as anti-cancer agents
KR20090057416A (en) 2006-10-05 2009-06-05 씨브이 쎄러퓨틱스, 인코포레이티드 Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl COA desaturase inhibitors
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN103524431B (en) * 2013-09-24 2016-01-13 西安交通大学 3-benzyl-4-quianzolinones and synthetic method thereof and application
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
FR3046793B1 (en) * 2016-01-14 2018-01-05 Les Laboratoires Servier NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9714222A (en) * 1996-12-17 2000-04-18 Du Pont Method for controlling plant diseases
PA8539301A1 (en) * 2001-02-14 2002-09-30 Warner Lambert Co INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX
PA8539401A1 (en) * 2001-02-14 2002-10-28 Warner Lambert Co QUINAZOLINAS AS INHIBITORS OF MMP-13

Also Published As

Publication number Publication date
WO2003076416A1 (en) 2003-09-18
UY27700A1 (en) 2003-10-31
IL163818A0 (en) 2005-12-18
AP2004003125A0 (en) 2004-09-30
EP1492775A2 (en) 2005-01-05
AU2003212307A1 (en) 2003-09-22
PA8568501A1 (en) 2003-12-19
OA12782A (en) 2006-07-10
NO20044041L (en) 2004-10-07
EA200401053A1 (en) 2005-04-28
CN1738806A (en) 2006-02-22
WO2003076417A2 (en) 2003-09-18
AR039562A1 (en) 2005-02-23
BR0308280A (en) 2004-12-28
KR20040095270A (en) 2004-11-12
SV2003001495A (en) 2003-11-04
CA2478706A1 (en) 2003-09-18
TNSN04169A1 (en) 2007-03-12
PL372622A1 (en) 2005-07-25
IS7414A (en) 2004-08-19
MXPA04008681A (en) 2004-12-06
MA27183A1 (en) 2005-01-03
CO5601020A2 (en) 2006-01-31
AU2002249275A1 (en) 2003-09-22
WO2003076417A3 (en) 2003-11-13
PE20031018A1 (en) 2004-01-09
JP2005526070A (en) 2005-09-02

Similar Documents

Publication Publication Date Title
ECSP045278A (en) OXO-AZABYCLIC COMPOUNDS
ES2190396T3 (en) NEW AMINO-TRIAZOL COMPOUNDS, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
PA8582801A1 (en) NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE
PE20050012A1 (en) BENZOPYRANE COMPOUNDS AS CYCLOOXYGENASE-2 INHIBITORS
ECSP034460A (en) NEW HETEROCICLIC COMPOUNDS, ITS PREPARATION AND ITS USE AS MEDICATIONS, IN SPECIAL AS ANTIBACTERIALS
AR245447A1 (en) Substituted pyrimidines, their synthesis and compositions containing them, their use in medicine and intermediates for making them
AR008377A1 (en) A COMPOUND DERIVED FROM 3-AROYLBENCIL-PIRIDAZINONE, A PARTICULAR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES CONTAINING SUCH A COMPOUND
ES2137998T3 (en) NEW AMINO ACID DERIVATIVES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINED IN THESE COMPOUNDS.
AR026173A1 (en) INHIBITORS OF NEURAMINIDASES.
UY29312A1 (en) PIPERAZIN-1-CARBOXAMIDAS N, 4, SUBSTITUTES AND THEIR DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
EA200300044A1 (en) NEW SUBSTITUTED PHTHALIDES, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
AR027335A1 (en) PIPERIDINE-4-SULFONAMIDE COMPOUNDS, SAME PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2183492T3 (en) NEW NITRON DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2114721T3 (en) PROCEDURE FOR PREPARING INTERMEDIATES DERIVED FROM BENZOIC ACID AND BENZOTIOFEN PHARMACEUTICAL AGENTS.
CO5590934A2 (en) EQUINOCANDINA DERIVATIVES PREPARATION PROCEDURE
ES2153019T3 (en) DERIVATIVES OF BENZO-DIOXANE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR027112A1 (en) PIPERAZINE DERIVATIVES SUBSTITUTED, ITS PREPARATION, ITS EMPLOYMENT AS MEDICATIONS
ES2153457T3 (en) AMINO-ALQUIL-BENZOXAZOLINONAS AND BENZOTIAZOLINONAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR029537A1 (en) NEW CYCLOPROPANIC COMPOUNDS 1,1- AND 1,2-DISUBSTITUTES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MX9603272A (en) Novel amino acid derivatives, method of producing them and pharmaceutical compositions containing these compounds.
ES2172376B1 (en) NEW DERIVATIVES OF ISOQUINOLEINS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2172023T3 (en) NEW SUBSTITUTED TETRAHYDRA-PYRIDINIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2172294T3 (en) NEW DERIVATIVES OF 1-INDANOL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR037498A1 (en) COMPOUND N- (4-AMIDINO-2,6-DIFLUOROBENZIL) -1- (2- (3-CHLORO-5- (DIFLUOROMETOXI) PHENYL) -2-HYDROXIACETILE) AZETIDINE-2-CARBOXAMIDE AND COMPOUND DERIVED FROM THE SAME, PHARMACEUTICAL COMPOSITION , ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT AND SYNTHETIC ROUTES FOR ITS PRODUCTION
DOP2003000603A (en) OXO-AZABICICLIC COMPOUNDS